U.S. markets closed
  • S&P Futures

    4,436.25
    -38.50 (-0.86%)
     
  • Dow Futures

    34,431.00
    -185.00 (-0.53%)
     
  • Nasdaq Futures

    14,635.50
    -205.50 (-1.38%)
     
  • Russell 2000 Futures

    2,007.00
    -14.20 (-0.70%)
     
  • Crude Oil

    86.29
    -0.61 (-0.70%)
     
  • Gold

    1,841.40
    -1.20 (-0.07%)
     
  • Silver

    24.45
    -0.27 (-1.08%)
     
  • EUR/USD

    1.1331
    +0.0014 (+0.12%)
     
  • 10-Yr Bond

    1.8330
    +0.0060 (+0.33%)
     
  • Vix

    25.59
    +1.74 (+7.30%)
     
  • GBP/USD

    1.3595
    -0.0005 (-0.03%)
     
  • USD/JPY

    113.7240
    -0.3760 (-0.33%)
     
  • BTC-USD

    39,658.18
    -2,336.14 (-5.56%)
     
  • CMC Crypto 200

    932.30
    -62.96 (-6.33%)
     
  • FTSE 100

    7,585.01
    -4.65 (-0.06%)
     
  • Nikkei 225

    27,377.44
    -395.49 (-1.42%)
     

Pacira BioSciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • PCRX

PARSIPPANY, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference at 7:00 AM ET on Monday, September 13, 2021. Pre-recorded audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

About Pacira

Pacira BioSciences, Inc. (Nasdaq: PCRX) is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera°® system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

CONTACT: Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.pedetti@pacira.com